ATE557007T1 - Arylpyrimidine geeignet zur behandlung von sexualhormonbedingten zuständen wie endometriose, prostatakrebs und dergleichen - Google Patents

Arylpyrimidine geeignet zur behandlung von sexualhormonbedingten zuständen wie endometriose, prostatakrebs und dergleichen

Info

Publication number
ATE557007T1
ATE557007T1 AT04756667T AT04756667T ATE557007T1 AT E557007 T1 ATE557007 T1 AT E557007T1 AT 04756667 T AT04756667 T AT 04756667T AT 04756667 T AT04756667 T AT 04756667T AT E557007 T1 ATE557007 T1 AT E557007T1
Authority
AT
Austria
Prior art keywords
sub
related conditions
arylpyrimidine
endometriosis
prostate cancer
Prior art date
Application number
AT04756667T
Other languages
English (en)
Inventor
Charles Huang
Chen Chen
Yongsheng Chen
Zhiqiang Guo
Warren Wade
Martin Rowbottom
Jaimie Rueter
Original Assignee
Neurocrine Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurocrine Biosciences Inc filed Critical Neurocrine Biosciences Inc
Application granted granted Critical
Publication of ATE557007T1 publication Critical patent/ATE557007T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Reproductive Health (AREA)
  • Immunology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Biomedical Technology (AREA)
  • Anesthesiology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT04756667T 2003-07-07 2004-07-06 Arylpyrimidine geeignet zur behandlung von sexualhormonbedingten zuständen wie endometriose, prostatakrebs und dergleichen ATE557007T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US48542403P 2003-07-07 2003-07-07
PCT/US2004/021568 WO2005007633A1 (en) 2003-07-07 2004-07-06 Gonadotropin-releasing hormone receptor antagonists and methods relating thereto

Publications (1)

Publication Number Publication Date
ATE557007T1 true ATE557007T1 (de) 2012-05-15

Family

ID=34079120

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04756667T ATE557007T1 (de) 2003-07-07 2004-07-06 Arylpyrimidine geeignet zur behandlung von sexualhormonbedingten zuständen wie endometriose, prostatakrebs und dergleichen

Country Status (6)

Country Link
US (2) US7015226B2 (de)
EP (1) EP1644342B1 (de)
JP (2) JP4673847B2 (de)
AT (1) ATE557007T1 (de)
ES (1) ES2387495T3 (de)
WO (1) WO2005007633A1 (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001055119A2 (en) * 2000-01-25 2001-08-02 Neurocrine Biosciences, Inc. Gonadotropin-releasing hormone receptor antagonists and methods relating thereto
US6995125B2 (en) * 2000-02-17 2006-02-07 The Procter & Gamble Company Detergent product
JP4673847B2 (ja) * 2003-07-07 2011-04-20 ニューロクライン バイオサイエンシーズ，インコーポレイテッド 性腺刺激ホルモン放出ホルモンレセプターアンタゴニストおよびそれに関連する方法
EP1646389B1 (de) * 2003-07-07 2008-09-10 Neurocrine Biosciences, Inc. Pyrimidin-2,4-dion-derivate als gonadotropin freisetzende hormon-rezeptor-antagonisten
BRPI0412327A (pt) 2003-07-07 2006-09-05 Neurocrine Biosciences Inc derivados de pirimidina-2,4-diona como antagonistas de receptor de hormÈnio liberador de gonadotropina
CN102079743B (zh) * 2004-03-15 2020-08-25 武田药品工业株式会社 二肽基肽酶抑制剂
US8263588B2 (en) 2007-04-06 2012-09-11 Neurocrine Biosciences, Inc. Gonadotropin-releasing hormone receptor antagonists and methods relating thereto
ES2534573T3 (es) 2007-04-06 2015-04-24 Neurocrine Biosciences, Inc. Antagonistas del receptor de la hormona liberadora de gonadotropina y métodos relacionados con los mismos
US8765948B2 (en) * 2007-11-07 2014-07-01 Neurocrine Biosciences, Inc. Processes for the preparation of uracil derivatives
CN107935863A (zh) * 2017-11-30 2018-04-20 厦门海乐景生化有限公司 Elagolix的关键原料化合物C的合成方法
WO2019115019A1 (en) * 2017-12-11 2019-06-20 Synthon B.V. Process for preparing elagolix
BR112021000973A2 (pt) 2018-07-23 2021-04-20 Abbvie Inc. composições e processos de sódio de elagolix
CN109761912A (zh) * 2019-02-16 2019-05-17 安徽诺全药业有限公司 一种多取代嘧啶衍生物的合成方法
CN113125575B (zh) * 2019-12-31 2023-04-18 济南尚博生物科技有限公司 一种1-(2-氟-6-(三氟甲基)苄基)-6-甲基嘧啶-二酮的定量分析方法

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2213510A1 (en) 1995-06-01 1996-12-05 Takeda Chemical Industries, Ltd. Diazepinones, their production and use
CN1063446C (zh) 1995-10-19 2001-03-21 武田药品工业株式会社 作为促性腺激素释放激素拮抗剂的噻吩并吡啶衍生物
AU7333496A (en) 1995-10-19 1997-05-07 Takeda Chemical Industries Ltd. Quinoline derivatives as gnrh antagonists
CZ183198A3 (cs) 1995-12-14 1998-10-14 Merck And Co., Inc. Nepeptidové deriváty, antagonizující hormon, uvolňující gonadotropin a farmaceutický prostředek
HUP9902121A3 (en) 1995-12-14 2001-05-28 Merck & Co Inc Indole derivatives as antagonists of gonadotropin releasing hormone and pharmaceutical compositions containing them
DE69620241T2 (de) 1995-12-14 2002-10-02 MERCK & CO., INC. (A NEW JERSEY CORP.) Gonadotropin releasing hormon- antagonisten
EP0868178A4 (de) 1995-12-14 2000-03-29 Merck & Co Inc Antagonisten des gonadotropin releasing hormons
AU728988B2 (en) 1997-06-05 2001-01-25 Merck & Co., Inc. Antagonists of gonadotropin releasing hormone
AU729752B2 (en) 1997-06-05 2001-02-08 Merck & Co., Inc. Antagonists of gonadotropin releasing hormone
CA2291647A1 (en) 1997-06-05 1998-12-10 Merck & Co., Inc. Antagonists of gonadotropin releasing hormone
CA2291829A1 (en) 1997-06-05 1998-12-10 Merck & Co., Inc. Antagonists of gonadotropin releasing hormone
US6313301B1 (en) 1997-08-13 2001-11-06 Takeda Chemical Industries, Ltd. Thienopyridine derivatives, their intermediates and production thereof
WO2000029386A1 (en) * 1998-11-12 2000-05-25 Merck & Co., Inc. Pyrimidinedione derivatives useful as alpha 1a adrenoceptor antagonists
MXPA01011634A (es) 1999-05-14 2002-07-30 Neurocrine Biosciences Inc Imidazo- y pirrolo [1,2-a]pirimid-4-onas como antagonistas receptores de la hormona liberadora de gonadotropina.
US20020065309A1 (en) 1999-08-04 2002-05-30 Ge Peng Novel Bicyclic and tricyclic pyrrolidine derivatives as GnRH antagonists
WO2001029044A1 (en) 1999-10-15 2001-04-26 Neurocrine Biosciences, Inc. Gonadotropin-releasing hormone receptor antagonists and methods relating thereto
WO2001055119A2 (en) * 2000-01-25 2001-08-02 Neurocrine Biosciences, Inc. Gonadotropin-releasing hormone receptor antagonists and methods relating thereto
SE0100566D0 (sv) 2001-02-20 2001-02-20 Astrazeneca Ab Compounds
AU2002324586B2 (en) 2001-08-02 2008-04-24 Neurocrine Biosciences, Inc. 1,3,5-triazine-2,4,6-triones, preparation and use as gonadotropin-releasing hormone receptor antagonists
MXPA04000986A (es) 2001-08-02 2005-02-17 Neurocrine Biosciences Inc 1,2,3-triazin-3,5-dionas sustituidas como antagonistas del receptor de hormona de liberacion de gonadotropina (gnrh).
JP2005505525A (ja) 2001-08-02 2005-02-24 ニューロクライン バイオサイエンシーズ， インコーポレイテッド 性腺刺激ホルモン放出ホルモンレセプターアンタゴニストおよびそれに関連する方法
WO2003011870A1 (en) 2001-08-02 2003-02-13 Neurocrine Biosciences, Inc. Gonadotropin-releasing hormone receptor antagonists
WO2003011293A2 (en) 2001-08-02 2003-02-13 Neurocrine Biosciences, Inc. Pyridinone and pyridazinone derivatives as gonadotropin-releasing hormone receptor antagonists
BRPI0412327A (pt) * 2003-07-07 2006-09-05 Neurocrine Biosciences Inc derivados de pirimidina-2,4-diona como antagonistas de receptor de hormÈnio liberador de gonadotropina
JP4673847B2 (ja) * 2003-07-07 2011-04-20 ニューロクライン バイオサイエンシーズ，インコーポレイテッド 性腺刺激ホルモン放出ホルモンレセプターアンタゴニストおよびそれに関連する方法
EP1646389B1 (de) * 2003-07-07 2008-09-10 Neurocrine Biosciences, Inc. Pyrimidin-2,4-dion-derivate als gonadotropin freisetzende hormon-rezeptor-antagonisten

Also Published As

Publication number Publication date
JP2007521307A (ja) 2007-08-02
JP2011079857A (ja) 2011-04-21
EP1644342B1 (de) 2012-05-09
ES2387495T3 (es) 2012-09-25
EP1644342A1 (de) 2006-04-12
JP4673847B2 (ja) 2011-04-20
US7229995B2 (en) 2007-06-12
WO2005007633A1 (en) 2005-01-27
US20060122204A1 (en) 2006-06-08
US7015226B2 (en) 2006-03-21
US20050038056A1 (en) 2005-02-17

Similar Documents

Publication Publication Date Title
DE602004016516D1 (de) Pyrimidin-2,4-dion-derivate als gonadotropin freisetzende hormon-rezeptor-antagonisten
DE602004020638D1 (de) Pyrimidin-2,4-dion-derivate als gonadotropin freisetzende hormon-rezeptor-antagonisten
DK1255738T3 (da) Gonadotropin-frigivende hormonreceptor-antagonister og fremgangsmåder relateret dertil
ATE557007T1 (de) Arylpyrimidine geeignet zur behandlung von sexualhormonbedingten zuständen wie endometriose, prostatakrebs und dergleichen
IS8502A (is) Azatvíhringja heteróhringir sem kannabínóíð-viðtakastillar
MY129348A (en) Stable polymorph of n-(3-ethynylphenyl)-6, 7-bis (2-methoxyethoxy)-4- quinazolinamine hydrochloride, methods of production, and pharmaceutical uses thereof
ATE355288T1 (de) Verbindungen und therapeutische methoden
DE602004006994D1 (en) 3-aryloxy und 3-heteroaryloxy substituierte benzo(b) thiophene als therapeutische wirkstoffe mit pi3k aktivität
DE60022769D1 (de) Gonadotropin freisetzenden hormon rezeptor antagonisten und ihre verwandten verwendungen
WO2003011293A3 (en) Pyridinone and pyridazinone derivatives as gonadotropin-releasing hormone receptor antagonists
MY133503A (en) Selective iglur5 receptor antagonists for the treatment of migrane
MXPA05013210A (es) Benzo[b]tiofenos cicloalquilsulfanil-sustituidos como agentes terapeuticos.
MXPA05012953A (es) Benzo[b]tiofenos 3-arilsulfanil y 3-heteroarilsulfanil sustituidos como agentes terapeuticos.
IL157457A0 (en) Benzimidazoles that are useful in treating sexual dysfuction
ATE316078T1 (de) 1,3,5-triazine-2,4,6-trione, herstellung und anwendungen als antagonisten der gonadotropin- freisetzenden hormonrezeptoren
MXPA03004547A (es) Agonistas receptores de d4 de dopamina selectivos para el tratamiento de disfuncion sexual.
DE60226313D1 (de) Verwendung von sesquiterpene enthaltenden zusammenstellungen zur behandlung von krebs
ATE398131T1 (de) Kondensierte camptothecine als antitumormittel
DE60102231D1 (de) Crf rezeptor-antagonisten und darauf bezogene methoden
SE0004780D0 (sv) Novel compunds
MY139385A (en) Benzimidazoles that are useful in treating sexual dysfunction
MY139582A (en) Benzimidazoles that are useful in treating sexual dysfunction
MY155220A (en) Selective dopamine d4 receptor agonists for treating sexual dysfunction
ECSP993058A (es) Antagonistas de la hormona liberadora de gonadotropina